X
<

Pfizer’s 2017 Performance in Review

PART:
1 2 3 4 5 6 7 8 9 10 11 12
Part 10
Pfizer’s 2017 Performance in Review PART 10 OF 12

How Did Pfizer’s Legacy Established Products Segment Perform in 2017?

PFE’s Legacy Established Product Segment revenue trends

In the fiscal year 2017, Pfizer’s (PFE) LEP (Legacy Established Products) segment reported net revenues of $10.89 billion, compared with $11.20 billion in 2016. In 2017, in the US and outside the US (international markets), Pfizer’s LEP segment reported revenues of $3.34 billion and $7.56 billion, respectively, compared with $3.76 billion and $7.44 billion in 2016.

In 4Q17, Pfizer’s (PFE) LEP segment generated revenues of $2.9 billion, which was ~3% higher on a YoY (year-over-year) basis. In 4Q17, in the US and in international markets, Pfizer’s LEP segment generated revenues of $788 million and $2.1 billion, respectively, compared with $893 million and $1.9 billion in 4Q16.

How Did Pfizer’s Legacy Established Products Segment Perform in 2017?

Interested in NVS? Don't miss the next report.

Receive e-mail alerts for new research on NVS

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Lipitor revenue trends

In 4Q17, Pfizer’s (PFE) Lipitor reported revenues of $574 million, which was 24% higher YoY and 17% higher on a quarter-over-quarter basis.

In fiscal 2017, Lipitor reported revenues of $1.9 billion, which was ~9% higher on a YoY basis. In 2017, in the US and in international markets, Lipitor reported revenues of $161 million and $1.75 billion, respectively, compared with $164 million and $1.59 billion in 2016.

In the marketplace, Lipitor (atorvastatin calcium) faces stiff competition from Merck’s (MRK) Zocor, AstraZeneca’s (AZN) Crestor, and Novartis’s (NVS) Lescol.

Norvasc revenue trends

In 4Q17, Norvasc reported revenues of $241 million, which represents a ~3% decline on a YoY basis but a 7% rise quarter-over-quarter.

In fiscal 2017, Norvasc generated revenues of $926 million, which was ~4% lower on a YoY basis. In 2017, in the US and in international markets, Norvasc reported revenues of $38 million and $888 million, respectively, which reflected a ~1% rise and a 4% fall, respectively, on a YoY basis.

Norvasc is used to treat hypertension and coronary arterial diseases.

Premarin revenue trends

In 4Q17, Premarin reported revenues of $266 million, which was ~12% higher on a quarter-over-quarter basis. In 4Q17, Premarin’s YoY revenues remained flat.

In fiscal 2017, Premarin reported revenues of $977 million, which was ~4% lower on a YoY basis. In 2017, in the US and in international markets, Premarin reported revenues of $921 million and $56 million, respectively, compared with $956 million and $60 million in 2016.

Continue to the next part for a closer look at the performance of Pfizer’s Rare Disease segment in 4Q17 and 2017.

X

Please select a profession that best describes you: